Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthrough marks UX-GIP001 as the first iPSC-derived allogeneic epilepsy cell therapy approved in the U.S. and simultaneously establishes it as...
POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on “AI + Medical-Grade Smart Wearables” to Build a New Ecosystem for Full-Cycle Chronic Disease Management
GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management". The Company plans to accelerate related technology research and development ("R&D")...
Esaote at EAU 2026: Introducing Exclusive PAM Technology to Advance Precision in Urological Imaging
The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth LONDON, March 13, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is reinforcing...
Everest Medicines’ Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm Potentially best-in-class durability with a favorable safety profile and...
Aphranel Named to Forbes China Beauty 100 List
SHANGHAI, March 13, 2026 /PRNewswire/ -- Aphranel, a China-origin regenerative medical aesthetics brand under the company SHANGHAI MOYANG BIOTECHNOLOGY, has been named to the Third Forbes China Beauty 100 list, published by Forbes China, which recognizes brands in China's beauty and medical aesthetics sector for their innovation and growth potential. The recognition reflects Aphranel's continued investment in product development, brand building, and...
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 13, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards (ABEA), achieving a historic record for the most accolades received in a single year. These recognitions underscore the...
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a...
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated,...
Emerald Clinical Trials Honored with 2026 Asia Pacific Biopharma Excellence Award for Outstanding Patient Recruitment & Engagement
SINGAPORE, March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization (CRO), today announced it has been named a winner of a 2026 Asia Pacific Biopharma Excellence Award (ABEA). The company was recognized with the Best Clinical Trials Supplier Award: Outstanding Patient Recruitment & Engagement. The ABEA award...
Rebelution Partners with Best 365 Labs and Growvana to Scale Science-Backed Cellular Health on Amazon and Beyond
Pioneering NAD and Mitochondrial Optimization Company Taps Rebelution E-Commerce's Infrastructure to Deliver Affordable, Ground-Zero Natural Health and Wellness to Everyone. CHICAGO, March 12, 2026 /PRNewswire/ -- Rebelution, a full-service e-commerce agency and operational infrastructure provider powered by Growvana, today announced a strategic partnership with Best 365 Labs, a wholly owned subsidiary of Bioscience Health...
